JP2018509908A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018509908A5 JP2018509908A5 JP2017548953A JP2017548953A JP2018509908A5 JP 2018509908 A5 JP2018509908 A5 JP 2018509908A5 JP 2017548953 A JP2017548953 A JP 2017548953A JP 2017548953 A JP2017548953 A JP 2017548953A JP 2018509908 A5 JP2018509908 A5 JP 2018509908A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- drug
- host cell
- seq
- following formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562134981P | 2015-03-18 | 2015-03-18 | |
| US62/134,981 | 2015-03-18 | ||
| PCT/US2016/022943 WO2016149535A1 (en) | 2015-03-18 | 2016-03-17 | Cd48 antibodies and conjugates thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020091335A Division JP2020141700A (ja) | 2015-03-18 | 2020-05-26 | Ｃｄ４８抗体及びその複合体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018509908A JP2018509908A (ja) | 2018-04-12 |
| JP2018509908A5 true JP2018509908A5 (https=) | 2019-03-07 |
| JP6892826B2 JP6892826B2 (ja) | 2021-06-23 |
Family
ID=56919489
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017548953A Expired - Fee Related JP6892826B2 (ja) | 2015-03-18 | 2016-03-17 | Ｃｄ４８抗体及びその複合体 |
| JP2020091335A Pending JP2020141700A (ja) | 2015-03-18 | 2020-05-26 | Ｃｄ４８抗体及びその複合体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020091335A Pending JP2020141700A (ja) | 2015-03-18 | 2020-05-26 | Ｃｄ４８抗体及びその複合体 |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US10722592B2 (https=) |
| EP (2) | EP3270965B1 (https=) |
| JP (2) | JP6892826B2 (https=) |
| KR (1) | KR20170128256A (https=) |
| CN (1) | CN107530422B (https=) |
| AU (1) | AU2016232839B2 (https=) |
| BR (1) | BR112017019617A2 (https=) |
| CA (1) | CA2976740A1 (https=) |
| DK (1) | DK3270965T3 (https=) |
| EA (2) | EA201992756A3 (https=) |
| ES (1) | ES2795818T3 (https=) |
| IL (1) | IL254027B (https=) |
| MX (1) | MX382582B (https=) |
| SG (1) | SG11201706786UA (https=) |
| WO (1) | WO2016149535A1 (https=) |
| ZA (1) | ZA201705935B (https=) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20180134351A (ko) | 2016-03-25 | 2018-12-18 | 시애틀 지네틱스, 인크. | 페길화된 약물-링커 및 그의 중간체의 제조를 위한 공정 |
| AU2018237683A1 (en) | 2017-03-24 | 2019-10-31 | Seagen Inc. | Process for the preparation of glucuronide drug-linkers and intermediates thereof |
| MX2020012718A (es) | 2018-05-29 | 2021-02-16 | Intocell Inc | Derivados de benzodiazepinas novedosos y usos de los mismos. |
| TWI851577B (zh) | 2018-06-07 | 2024-08-11 | 美商思進公司 | 喜樹鹼結合物 |
| KR20210068591A (ko) | 2018-10-31 | 2021-06-09 | 주식회사 인투셀 | 융합된 헤테로시클릭 벤조디아제핀 유도체 및 그의 용도 |
| WO2020163225A1 (en) * | 2019-02-05 | 2020-08-13 | Seattle Genetics, Inc. | Anti-cd228 antibodies and antibody-drug conjugates |
| CN114269749B (zh) | 2019-06-10 | 2024-10-01 | 苏特罗生物制药公司 | 5H-吡咯并[3,2-d]嘧啶-2,4-二氨基化合物及其抗体偶联物 |
| WO2021067820A1 (en) | 2019-10-04 | 2021-04-08 | Seagen Inc. | Formulation of antibody-drug conjugate |
| AU2020358859A1 (en) | 2019-10-04 | 2022-05-12 | Seagen Inc. | Anti-PD-L1 antibodies and antibody-drug conjugates |
| AU2020356955A1 (en) | 2019-10-04 | 2022-04-14 | Seagen Inc. | Camptothecin peptide conjugates |
| WO2021207701A1 (en) | 2020-04-10 | 2021-10-14 | Seagen Inc. | Charge variant linkers |
| CA3200858A1 (en) * | 2020-11-24 | 2022-06-02 | Novartis Ag | Anti-cd48 antibodies, antibody drug conjugates, and uses thereof |
| US20240042051A1 (en) * | 2020-11-24 | 2024-02-08 | Francesca Rocchetti | Mcl-1 inhibitor antibody-drug conjugates and methods of use |
| AU2022238571A1 (en) | 2021-03-18 | 2023-09-14 | Seagen Inc. | Selective drug release from internalized conjugates of biologically active compounds |
| CA3221398A1 (en) | 2021-05-28 | 2022-12-01 | Seagen Inc. | Anthracycline antibody conjugates |
| IL315508A (en) | 2022-03-17 | 2024-11-01 | Seagen Inc | Camptothecin conjugates |
| WO2024129756A1 (en) | 2022-12-13 | 2024-06-20 | Seagen Inc. | Site-specific engineered cysteine antibody drug conjugates |
| AR132368A1 (es) | 2023-04-18 | 2025-06-18 | Astrazeneca Ab | Conjugados que comprenden enlazadores escindibles |
| TW202525851A (zh) | 2023-08-15 | 2025-07-01 | 瑞典商阿斯特捷利康公司 | 包含可切割連接子的軛合物 |
| WO2025090774A1 (en) | 2023-10-24 | 2025-05-01 | Seagen Inc. | Chemotherapeutic compounds and methods of use |
| WO2025149947A1 (en) | 2024-01-12 | 2025-07-17 | Seagen Inc. | Antibody-drug conjugates |
| WO2025185617A1 (en) * | 2024-03-05 | 2025-09-12 | Hutchmed Limited | Linker, antibody-drug conjugate and use thereof |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| WO1988007089A1 (en) | 1987-03-18 | 1988-09-22 | Medical Research Council | Altered antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| CA2249998A1 (en) * | 1996-03-27 | 1997-10-02 | Crc For Biopharmaceutical Research Pty. Ltd. | The use of antibodies against cd48 for the treatment of t and b cell lymphomas and leukemias |
| US5834597A (en) | 1996-05-20 | 1998-11-10 | Protein Design Labs, Inc. | Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same |
| MXPA05000511A (es) | 2001-07-12 | 2005-09-30 | Jefferson Foote | Anticuepros super humanizados. |
| SI1545613T1 (sl) | 2002-07-31 | 2011-11-30 | Seattle Genetics Inc | Avristatinski konjugati in njihova uporaba za zdravljenje raka avtoimunske bolezni ali infekcijskebolezni |
| US7498298B2 (en) | 2003-11-06 | 2009-03-03 | Seattle Genetics, Inc. | Monomethylvaline compounds capable of conjugation to ligands |
| JPWO2005094886A1 (ja) * | 2004-03-31 | 2008-02-14 | キリンファーマ株式会社 | Ｇｐｉアンカー蛋白質アゴニストによる調節性ｔ細胞分化誘導・増殖方法およびそのための医薬組成物 |
| SG173322A1 (en) * | 2004-04-16 | 2011-08-29 | Macrogenics Inc Dw Us | Fc gammad riib - specific antibodies and methods of use thereof |
| US8871720B2 (en) | 2005-07-07 | 2014-10-28 | Seattle Genetics, Inc. | Monomethylvaline compounds having phenylalanine carboxy modifications at the C-terminus |
| JP5171621B2 (ja) | 2005-07-07 | 2013-03-27 | シアトル ジェネティックス， インコーポレイテッド | フェニルアラニン側鎖修飾をｃ末端に有するモノメチルバリン化合物 |
| HUE035853T2 (en) * | 2005-07-18 | 2018-05-28 | Seattle Genetics Inc | Beta-glucuronide-linker-drug conjugates |
| HRP20130494T1 (en) * | 2005-12-20 | 2013-08-31 | Sbi Biotech Co., Ltd. | Anti-ilt7 antibody |
| RU2476441C2 (ru) | 2007-10-19 | 2013-02-27 | Сиэтл Дженетикс, Инк. | Cd19-связывающие средства и их применение |
| UA104132C2 (en) * | 2007-11-13 | 2014-01-10 | Тева Биофармасьютикалз Юесей, Инк. | Humanized antibodies against tl1a |
| WO2009099580A2 (en) * | 2008-02-05 | 2009-08-13 | Monsanto Technology, Llc | Isolated novel nucleic acid and protein molecules from soy and methods of using those molecules to generate transgenic plants with enhanced agronomic traits |
| WO2010117059A1 (ja) | 2009-04-10 | 2010-10-14 | 国立大学法人大阪大学 | 形質細胞の腫瘍性増殖をきたす疾患の治療薬 |
| EP2287197A1 (en) * | 2009-08-21 | 2011-02-23 | Pierre Fabre Medicament | Anti-cMET antibody and its use for the detection and the diagnosis of cancer |
| AR083044A1 (es) * | 2010-09-27 | 2013-01-30 | Regeneron Pharma | Anticuerpos anti-cd48 y usos de los mismos |
| BR112013026199A2 (pt) * | 2011-04-15 | 2017-11-07 | Compugen Ltd | polipeptídeo isolado, proteína de fusão, sequência de ácidos nucleicos, vetor de expressão ou um vírus, célula recombinante, método de produção de um polipeptídeo com ectodomínio solúvel lsr, ou seu fragmento ou proteína de fusão, composição farmacêutica, uso de um anticorpo monoclonal ou policlonal ou um seu fragmento de ligação ao antígeno, uso do anticorpo ou do fragmento de ligação ao antígeno, uso de qualquer um de um polipeptídeo isolado, método de regulação por cima de citocinas, indução da expansão de células t, promoção da imunidade de células t específica antigênica e promoção da ativação das células t cd4+ e/ou cd8+ em um sujeito, método para potenciação de uma resposta imune secundária a um antígeno em um paciente, método de uso de pelo menos um de: um polipeptídeo isolado, método para tratamento ou prevenção de uma condição relacionada com o sistema imune, método para tratamento ou prevenção de uma doença infecciosa, método para diagnóstico de uma doença em um sujeito, método de produção de um polipeptídeo com ectodomínio solúvel tmem25, vsig10, ly6g6f, ou seu fragmento ou proteína de fusão, anticorpo monoclonal ou policlonal ou um seu fragmento de ligação ao antígeno, método de imunoterapia em um paciente e método para combinação de vacinação terapêutica com um antígeno em conjunto com a administração de qualquer um de um polipeptídeo |
| KR101721678B1 (ko) * | 2012-03-08 | 2017-03-31 | 할로자임, 아이엔씨 | 조건부 활성 항-표피 성장 인자 수용체 항체 및 이의 사용 방법 |
| KR102557309B1 (ko) * | 2012-05-15 | 2023-07-20 | 씨젠 인크. | 자가-안정화 링커 접합체 |
| ES2826398T3 (es) * | 2013-10-15 | 2021-05-18 | Seagen Inc | Enlazadores-fármacos pegilados para una mejor farmacocinética de los conjugados ligando-fármaco |
-
2016
- 2016-03-17 MX MX2017011432A patent/MX382582B/es unknown
- 2016-03-17 CA CA2976740A patent/CA2976740A1/en not_active Abandoned
- 2016-03-17 AU AU2016232839A patent/AU2016232839B2/en not_active Ceased
- 2016-03-17 JP JP2017548953A patent/JP6892826B2/ja not_active Expired - Fee Related
- 2016-03-17 CN CN201680013161.1A patent/CN107530422B/zh not_active Expired - Fee Related
- 2016-03-17 US US15/557,910 patent/US10722592B2/en active Active
- 2016-03-17 BR BR112017019617-4A patent/BR112017019617A2/pt not_active IP Right Cessation
- 2016-03-17 EP EP16765773.3A patent/EP3270965B1/en active Active
- 2016-03-17 SG SG11201706786UA patent/SG11201706786UA/en unknown
- 2016-03-17 EA EA201992756A patent/EA201992756A3/ru unknown
- 2016-03-17 ES ES16765773T patent/ES2795818T3/es active Active
- 2016-03-17 EP EP19219476.9A patent/EP3662933A1/en not_active Withdrawn
- 2016-03-17 EA EA201792055A patent/EA035374B1/ru unknown
- 2016-03-17 WO PCT/US2016/022943 patent/WO2016149535A1/en not_active Ceased
- 2016-03-17 KR KR1020177024226A patent/KR20170128256A/ko not_active Withdrawn
- 2016-03-17 DK DK16765773.3T patent/DK3270965T3/da active
-
2017
- 2017-08-16 IL IL254027A patent/IL254027B/en active IP Right Grant
- 2017-08-31 ZA ZA2017/05935A patent/ZA201705935B/en unknown
-
2020
- 2020-05-26 JP JP2020091335A patent/JP2020141700A/ja active Pending
- 2020-06-04 US US16/892,529 patent/US20200289661A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018509908A5 (https=) | ||
| CA3093327C (en) | Targeted cd73 antibody and antibody-drug conjugate, and preparation method therefor and uses thereof | |
| JP6608467B2 (ja) | 生体直交型薬物活性化 | |
| ES2701188T3 (es) | Conjugados anticuerpo-fármaco e inmunotoxinas | |
| US10752690B2 (en) | Biologically active molecule conjugates, reagents and methods of manufacture, and therapeutic uses | |
| AU2014224928B2 (en) | Amatoxin derivatives | |
| JP2024522389A (ja) | 抗体薬物複合体の調製方法および使用 | |
| ES2939494T3 (es) | Conjugados de fármaco anticuerpo que comprenden derivados de ecteinascidina | |
| US20200392108A1 (en) | Antibody-drug conjugates and related compounds, compositions and methods | |
| CN117295526B (zh) | 制备工程化抗体的高度均质性抗体-药物偶联物的方法 | |
| JP6321687B2 (ja) | アマトキシン誘導体 | |
| JP2016523810A5 (https=) | ||
| JP2018524373A5 (https=) | ||
| JP2016531915A5 (https=) | ||
| JP2014515040A5 (https=) | ||
| JP2016503295A5 (https=) | ||
| JP2022500486A (ja) | 抗体−ａｌｋ５阻害剤コンジュゲートおよびその使用 | |
| FI3525828T3 (fi) | Anti-edb-vasta-aineita ja vasta-aine-lääke-konjugaatteja | |
| JP2019534706A5 (https=) | ||
| WO2023163227A1 (ja) | 抗体－薬物コンジュゲート | |
| JP7854462B2 (ja) | 抗体－ａｌｋ５阻害剤コンジュゲートおよびその使用 | |
| NZ773646A (en) | Amatoxin-antibody conjugates | |
| NZ730450B2 (en) | Binding molecules, especially antibodies, binding to l1cam (cd171) | |
| NZ773646B2 (en) | Amatoxin-antibody conjugates | |
| NZ747029A (en) | Novel b7-h3 binding molecules, antibody drug conjugates thereof and methods of use thereof |